ŌURA Doubles Down on Women's Health with Hormonal Birth Control Integration and Olympic Partnerships

ŌURA has secured official wearable partnerships with both Team USA and Team Finland for the 2026 and LA28 Olympic and Paralympic Games, marking the culmination of an aggressive 18-month expansion into women's reproductive health features that began with basic cycle tracking and now includes FDA-cleared birth control integration.

The Finnish wearable manufacturer announced its Team Finland partnership on February 23, 2026, following its February 6 designation as the Official Wearable of Team USA and LA28. These Olympic partnerships represent ŌURA's push beyond the consumer wellness market into performance monitoring for elite athletes, leveraging the same physiological sensors that power its reproductive health features.

From Cycle Tracking to Birth Control

ŌURA's reproductive health strategy centers on temperature-based cycle prediction through its ring's skin temperature sensors. The company's Cycle Insights feature tracks follicular and luteal phases via ovulation detection, providing cycle phases, fertility signals, and educational resources through the Oura app.

The key technical advancement came through ŌURA's integration with Natural Cycles, an FDA-cleared birth control app. Oura Ring members can access Natural Cycles free for 28 days, with the combined system claiming 93 percent effectiveness for typical use and 98 percent effectiveness with perfect use. The ring tracks overnight temperature trends and automatically syncs with Natural Cycles each morning, feeding data into the app's FDA-cleared algorithm optimized specifically for fertility tracking and birth control.

ŌURA expanded this hormonal health focus with new features for users on hormonal birth control, acknowledging that withdrawal bleeding differs from natural menstrual periods. The company also launched Menopause Insights as a dedicated experience within the Oura app and partnered with Twentyeight Health to connect U.S. members with licensed providers for birth control prescriptions directly through the platform.

Broader Femtech Context

The ring-based approach reflects the broader femtech wave targeting women's health with wearable technology. ŌURA competes directly with the Femometer Smart Ring and Evie Ring in the cycle-tracking smart ring category, all using similar sensor arrays to monitor sleep, heart function, and skin temperature for reproductive health insights.

The technical foundation remains consistent across platforms: smart rings detect the subtle temperature shifts that occur throughout the menstrual cycle, typically a 0.2-0.5 degree Celsius increase post-ovulation. This approach requires continuous overnight monitoring to establish baseline patterns and detect meaningful deviations.

Looking at the broader pattern here, we have seen this progression before with consumer health technology — initial adoption for general wellness metrics, followed by clinical validation for specific medical use cases, then integration with healthcare providers and prescription services. The glucose monitoring space followed a similar trajectory, moving from basic tracking to FDA-cleared medical devices integrated with telehealth platforms.

Financial and Technical Momentum

ŌURA's reproductive health push coincides with substantial funding rounds and hardware iterations. The company raised $200 million in Series D funding in December 2024, bringing its valuation to $5.2 billion with investments from Fidelity Management & Research Company and Dexcom. An additional $900 million funding round led by Fidelity followed in October 2025.

The Dexcom partnership represents strategic alignment beyond pure investment. Dexcom contributed $75 million to the Series D round and announced a strategic partnership in November 2024, potentially setting up glucose monitoring integration with ŌURA's existing physiological tracking capabilities.

Hardware development accelerated with the October 2024 launch of the Oura Ring 4, powered by Smart Sensing technology. ŌURA subsequently debuted ceramic versions in new colors and introduced multi-ring support with a new charging case in October 2025. The company also acquired metabolic health specialist Veri in September 2024, expanding its expertise beyond basic biometrics.

Commercial momentum reflects this technical development. ŌURA surpassed 2.5 million rings sold by June 2024 with membership growth exceeding 200 percent. By September 2025, the company had sold over 5.5 million rings and doubled revenue for the second consecutive year.

AI Integration and Ecosystem Expansion

ŌURA launched Oura Advisor in March 2025, an AI-powered personal health companion rolling out to all members. The system provides personalized insights based on the ring's continuous physiological monitoring, including reproductive health patterns alongside sleep, activity, and recovery metrics.

The company has built an expanding partner ecosystem around its core platform. Beyond the Natural Cycles and Twentyeight Health integrations, ŌURA partnered with Midi Health, Evernow, Maven Clinic, and Progyny for integrated menopause care in August 2025. It also secured its first UK retail partnership with John Lewis in May 2024, making Oura Ring available in all 34 John Lewis stores.

Enhanced activity features and partner ecosystem expansion continued through May 2025, with ŌURA introducing new fitness tracking capabilities and third-party integrations. The company unveiled preventive health capabilities in October 2025, including cumulative stress insights and a blood pressure profile study alongside a redesigned app interface.

Competitive and Regulatory Position

ŌURA strengthened its patent position with a September 2025 U.S. International Trade Commission ruling in its favor against competitors Ultrahuman and RingConn. This decision provides legal protection for ŌURA's core ring-based health monitoring technologies as the smart ring market expands.

The Olympic partnerships position ŌURA alongside traditional sports performance monitoring companies while maintaining its consumer health focus. These elite athlete endorsements provide validation for the ring's physiological tracking capabilities across both performance optimization and reproductive health applications.

The integration of FDA-cleared birth control functionality represents a significant regulatory milestone for consumer wearables, establishing precedent for smart ring medical device classification. This positions ŌURA at the intersection of consumer wellness and clinical healthcare, a space that requires navigating both FDA medical device regulations and consumer electronics standards.